Neuropathy and Anti-GFAP Antibodies (Neuro-GFAP)

Civil Hospices of Lyon

Status: Active, not recruiting

Conditions: Neurological Diseases Associated to Anti GFAP Antibodies; Neurological Diseases or Conditions

Treatments: Other: electroneuromyography (ENMG); Other: Clinical examination

Study type: Observational

Funder types: Other

Identifiers

NCT05742087

22-5018

Details and patient eligibility

About

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.

The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age > 18 years old
• Neurological symptoms
• Anti-GFAP antibodies identified in the CSF

Exclusion criteria

• • Uncomplete data in the medical records of patients

Trial design

120 participants in 1 patient group

Patients presenting with neurological symptoms and anti-GFAP antibodies in the CSF.

Description:

This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "iological Resource Center of the Hospices Civils de Lyon" (CRB-HCL) (including tissue, cells or biological fluids). The group will be composed of patients included in the French cohort of patients with neurological syndromes and anti-GFAP antibodies in the CSF.

Treatment:

Other: electroneuromyography (ENMG)

Other: Clinical examination